GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Total Assets

Outlook Therapeutics (FRA:41O) Total Assets : €16.24 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Total Assets?

Outlook Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was €16.24 Mil.

During the past 12 months, Outlook Therapeutics's average Total Assets Growth Rate was -0.20% per year. During the past 3 years, the average Total Assets Growth Rate was 18.60% per year. During the past 5 years, the average Total Assets Growth Rate was 9.10% per year. During the past 10 years, the average Total Assets Growth Rate was -10.40% per year.

During the past 11 years, Outlook Therapeutics's highest 3-Year average Total Assets Growth Rate was 18.60%. The lowest was -26.60%. And the median was -9.80%.

Total Assets is connected with ROA %. Outlook Therapeutics's annualized ROA % for the quarter that ended in Dec. 2024 was 314.53%. Total Assets is also linked to Revenue through Asset Turnover. Outlook Therapeutics's Asset Turnover for the quarter that ended in Dec. 2024 was 0.00.


Outlook Therapeutics Total Assets Historical Data

The historical data trend for Outlook Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Total Assets Chart

Outlook Therapeutics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.75 19.39 28.81 30.27 25.97

Outlook Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.89 54.31 43.75 25.97 16.24

Outlook Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Outlook Therapeutics's Total Assets for the fiscal year that ended in Sep. 2024 is calculated as

Total Assets=Total Equity (A: Sep. 2024 )+Total Liabilities (A: Sep. 2024 )
=-65.842+91.812
=25.97

Outlook Therapeutics's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (Q: Dec. 2024 )+Total Liabilities (Q: Dec. 2024 )
=-48.027+64.268
=16.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Outlook Therapeutics  (FRA:41O) Total Assets Explanation

Total Assets is connected with ROA %.

Outlook Therapeutics's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %=Net Income (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=66.384/( (25.97+16.241)/ 2 )
=66.384/21.1055
=314.53 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Outlook Therapeutics's Asset Turnover for the quarter that ended in Dec. 2024 is

Asset Turnover
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0/( (25.97+16.241)/ 2 )
=0/21.1055
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Outlook Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Outlook Therapeutics Business Description

Traded in Other Exchanges
Address
111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Outlook Therapeutics Headlines

No Headlines